Huateng News
HZ-PEG-HZ (1K) Successfully Completed The…
Huateng Pharma has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for our self-developed HZ-PEG-HZ (1K) product (DMF number: 041864)
Good News! mPEG-pALD (20K) Successfully C…
Huateng Pharma has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for our self-developed mPEG-pALD (20K) product (DMF number: 040600)
Huateng Pharma Completed Series B Round o…
Recently, Hunan Huateng Pharmaceutical Co., Ltd. completed a series B financing of 117 million yuan led by CITIC Securities.
Huateng Pharma CPHI Shanghai 2020 Exhibit…
On December 16, the 20th CPHI Shanghai 2020 (Chemical Pharmaceutical Ingredient) was grandly held at Shanghai New International Expo Centre (SNIEC), PR China.
Huateng Pharmaceutical Raised 50 Million …
On September 24, Hunan Huateng Pharmaceutical Co., Ltd. raised 50 million yuan in the series A round of funding led by Tasly Capitals Boyi Fund.
sales@huatengusa.com
+86 0731 89916275